Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Arch Biopartners Inc V.ARCH

Alternate Symbol(s):  ACHFF

Arch Biopartners Inc. is a portfolio-based biotechnology company focused on the development of technologies that have the potential to make a medical or commercial impact. The Company is focused on the clinical development of its drug platform in targeting dipeptidase-1 (DPEP-1) mediated organ inflammation in the lungs, liver and kidneys. Its lead drug candidate is LSALT Peptide (Metablok... see more

TSXV:ARCH - Post Discussion

View:
Post by Viking2233 on Sep 09, 2023 3:38pm

Buyers

Where are the buyers? The stock is trading below 2018 yet we have achieved many positive milestones, reduced the risk.

We are now below $100 million market cap yet many similar staged companies have much higher market caps in the $Billions.

They all have institutional ownership where we have zero%, in my opinion that falls directly back on management. What are they doing and why can't they generate interest from institutional big boys?

We are long overdue for the 3rd party independent phase 2 peer review, no
idea when we will receive or if it will even have any positive impact on share price. I am sure the one analyst who covers ARCH is scratching his head.

The new phase 2 AKI trial should be starting soon, I hope we get an update from management.

I am disappointed with share price and lack of buying interest. It is obvious that CIBC and Scotia are shorting the stock for about 12 months now but the real issue is the lack of buying, low volume. If there was serious buying interest the share price would be much higher.

I believe management have backed themselves into a corner here with regards to attracting institutional buyers do to the fact our share price is below $10, we are on the TSX Venture exchange, our market cap is below $1B and the volume and liquidity are a big concern for the big boys.

I am confident we will see stellar data and results from the new phase 2 AKI trial but the shorting action and trading suggests the markets are signaling dilution/capital raise in the future for a future phase 3 trial.
Comment by Arbourmark on Sep 11, 2023 10:14am
Well said Viking, I am on another discussion board and have been saying this for many months now but others on the board feel management can do no wrong. Management needs to figure out why there are no buyers and more importantly why there is 0% institutional ownership. what have they been doing for the past 18 months and what have the 2 strategic advisors brought to the table since being ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities